Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730691 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 781
- Enrollment target
NCT00730691: Completed Phase 3 study, sponsored by Takeda.
NCT00730691 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 781 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00730691, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 781 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
Primary Outcome
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00730691 record still lists
NCT00730691 is an interventional study that assigns participants to a tested intervention. The registered 781 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00730691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00730691 about?
NCT00730691 is a clinical study titled "Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder". The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
What is the current status of trial NCT00730691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 781 participants. The study started on 2008-06. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00730691?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT00730691?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00730691's enrollment target sits among peer trials
781 434th of 2000 higher than 1,567 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia